Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, Netherlands.
Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, Netherlands.
Lancet Glob Health. 2022 Apr;10(4):e570-e573. doi: 10.1016/S2214-109X(22)00075-4.
Despite tremendous efforts, worldwide COVID-19 vaccination coverage is lagging. Dose-sparing strategies for COVID-19 vaccines can increase vaccine availability to address the global crisis. Several clinical trials evaluating dose sparing are currently underway. However, to rapidly provide solid scientific justification for different dose-sparing strategies, joint coordinated action involving both public and private parties is needed. In this Viewpoint, we provide examples of approaches to vaccine dose-sparing that have previously been evaluated in clinical trials to improve vaccine availability and reflect on the origin of their funding. With a focus on the current COVID-19 pandemic, we stress the need for expedited testing of vaccine dose-sparing strategies in endemic or epidemic infectious diseases. However, we argue that the establishment of a mechanism through which dose-sparing opportunities are systematically identified, scientifically tested, and ultimately implemented will prove to be valuable beyond the current pandemic for infectious diseases product development and pandemic preparedness in the future.
尽管付出了巨大努力，但全球范围内的 COVID-19 疫苗接种覆盖率仍然滞后。COVID-19 疫苗的剂量节约策略可以增加疫苗的可及性，以应对全球危机。目前正在进行几项评估剂量节约的临床试验。然而，要为不同的剂量节约策略提供快速可靠的科学依据，需要公共和私营部门共同协调行动。在本观点中，我们提供了之前在临床试验中评估过的疫苗剂量节约方法的示例，以提高疫苗的可及性，并反思其资金来源。重点关注当前的 COVID-19 大流行，我们强调需要加快测试针对地方性或流行性传染病的疫苗剂量节约策略。然而，我们认为，建立一种通过该机制系统地识别、科学测试并最终实施剂量节约机会的机制，对于未来传染病产品开发和大流行防范而言，将证明其具有超越当前大流行的价值。
